Development of High Expression Plasmid Vectors for Herceptin and other Recombinant Proteins & Antibodies Production

Introduction

A proprietary expression vector with the transgene expressed under CMV promoter hence significantly increased expression level of the antibody. Refine Technology's ATF system was used.

Stage of Development

Proof of Concept.

Unique Features of Product/Technology

A proprietary mammalian expression vector has been developed to express high-level of recombinant antibodies in CHO cells. The CHO cell line has also been modified to prevent apoptosis, thereby increasing the lifespan of cells with higher yield of mAb. ATF system helps to attain volumetric productivity and reduces the cost of operation by reducing 9-step bioprocess to 3-step process.

Market Potential

Herceptin, is an expensive drug and can cost up to USD 3000 every month. Proposed goal is to develop a high-expresser mammalian cell line that can reduce the production cost.

National/Societal Relevance

Incidents of breast cancer in India are rising with almost 75,000 new cases every year. Herceptin reduces the risk of a relapse by 50% in fast-growing type of tumor in women. Herceptin is an expensive drug and can cost upto Rs 1.5 lakh every month, which is beyond the reach of most of the patients in India.

For further information please contact

Biotechnology Industry Research Assistance Council (BIRAC)

1 st Floor, MTNL Building, 9, CGO Complex,

Lodhi Road, New Delhi- 110003

Phone: + 91-11-24389600

Email- birac.dbt@nic.in